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Abstract: Despite advances in understanding potential disease mechanisms and in developing 
novel therapeutic approaches to the treatment of major depressive disorder, the disease contin-
ues to carry an enormous personal, social, and economic burden. Agomelatine represents an 
important opportunity to advance the treatment of depression. It is a melatonergic (MT1 and 
MT2) agonist and serotonergic (5HT2C) antagonist. Evidence from animal models of depression, 
complements emerging clinical data. In a dose range of 25–50 mg daily, agomelatine is an 
effective antidepressant with a very favorable side-effect proﬁ  le. In particular, sleep restorative 
action in the absence of sedation and minimal effect on sexual function suggests that agomelatine 
represents a worthwhile treatment alternative for patients with major depressive disorder.
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Introduction
Major depressive disorder carries an enormous personal, social, and economic 
burden. Despite a better understanding of disease mechanisms and neurobiological 
consequences of treatments, the effectiveness and tolerability of currently avail-
able antidepressants remain suboptimal (Kennedy et al 2001; Trivedi et al 2006). 
The current search for therapeutic targets has shifted from selective monoamine 
systems to monoamine and non-monoamine networks (Millan 2004).
Although the selective serotonin reuptake inhibitor (SSRI) antidepressants induce 
substantial side-effects, including initial anxiety, nausea, insomnia, sexual dysfunction, and 
weight gain, their safety and tolerability proﬁ  les remain superior to those of tricyclic and 
monoamine oxidase inhibitor antidepressants. Unfortunately, the evidence to support superior 
efﬁ  cacy of SSRIs is extremely limited. Dual action noradrenergic and serotonergic reuptake 
inhibitors (venlafaxine, duloxetine, milnacipran) appear to confer a modest advantage in 
remission rates compared with classical SSRIs (Lopez-Ibor et al 1996; Thase et al 2001; 
Smith et al 2002), but carry a similar side-effect burden to SSRIs (Vanderkooy et al 2002). 
Other mixed-action antidepressants, including trazodone, nefazodone, and mirtazapine, exert 
their antidepressant effects at least in part through antagonism of post-synaptic 5HT2A/2C 
receptors. This action has a favorable effect on sexual function and sleep and has also been 
shown to enhance cortical release of dopamine and norepinephrine (Millan et al 2003).
Recent evidence from preclinical (Vacher et al 2002; Bourin et al 2004; Bertaina-
Anglade et al 2006) and clinical (Loo et al 2002; Kennedy and Emsley 2006) studies 
suggests that agomelatine, a speciﬁ  c agonist of melatonergic-1 (MT1) and melatonergic-2 
(MT2) receptors and an antagonist of 5HT2C receptors (Audinot et al 2003; Millan et al 
2003) has promising antidepressant properties (den Boer et al 2006). The role of MT1 
and MT2 receptors in regulating the suprachiasmatic nucleus circadian clock suggests a 
mechanism to restore disruptions in the sleep-wake cycle and circadian rhythms.Neuropsychiatric Disease and Treatment 2007:3(4) 424
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Chemistry and clinical 
pharmacology
Agomelatine is an acetamide naphthalene analog of melatonin 
that is dispensed in capsule form. Investigations of the action of 
agomelatine on over 80 receptors and enzymes revealed neg-
ligible afﬁ  nity (IC50 > 10–5 M) for all potential targets except: 
MT1 (KI = 0.1 nM); MT2 (KI = 0.12 nM) (Audinot et al 2003); 
and 5HT2C (pKi = 6.2 μM) (Millan et al 2003). Although 
it also interacted with 5HT2B receptors, they are poorly 
represented in the central nervous system and have uncertain 
functional signiﬁ  cance (Duxon et al 1997). Consequent 
studies investigating the effect of acute and chronic treatment 
with agomelatine on the density of 5HT1A receptors and their 
coupling with G proteins in the dorsal raphe nucleus and the 
hippocampus in rats revealed no change in density (Hanoun 
et al 2004), in contrast to the action of a wide range of SSRI and 
tricyclic antidepressants (Pineyro and Blier 1999). In addition, 
agomelatine dose dependently blocked the induction of penile 
erections by 5HT2C agonists and dose dependently enhanced 
dialysis levels of noradrenaline and dopamine in the frontal 
cortex, but not in the nucleus accumbens or striatum of freely 
moving rats (Millan et al 2003). No effect on serotonin levels 
was observed (Millan et al 2005).
Agomelatine is absorbed rapidly by the oral route and 
metabolized in the liver through cytochrome P450 1A2 and 
2C9 isoenzymes, with metabolites predominantly excreted in 
urine (Bogaards et al 2000). The mean half-life of agomelatine 
is 2.3 hours. Co-administration of compounds that are 
metabolized by 1A2, including ﬂ  uvoxamine, a potent inhibitor 
of the 1A2 isoenzyme system, may result in increased plasma 
levels of agomelatine, while inducers of 1A2 such as caffeine 
or nicotine are likely to reduce agomelatine levels.
Preclinical evidence
The focus of animal studies was to compare the effects of 
agomelatine with melatonin particularly in phase shifting 
and circadian rhythm effects. A program of research has 
also been developed to investigate potential antidepressant 
properties in a number of recognized animal models for 
anxiety and depression.
Melatonin plays a major role in the regulation of 
body temperature (Krauchi and Wirz-Justice 2001) and 
consolidation of sleep (Dijk and Cajochen 1997). Elevated 
levels of melatonin activate the MT1 and MT2 receptors. 
Activation of MT1 receptors in the suprachiasmatic nucleus 
appears to inhibit neuronal ﬁ  ring and facilitate sleep, while 
activation of MT2 receptors phase shift circadian rhythms 
(Dubocovich 2006). As a melatonin agonist, agomelatine 
has also been shown to resynchronize circadian rhythms in 
animal models of delayed sleep-phase syndrome (Armstrong 
et al 1993; Redman et al 1995), in a dose-dependent and 
plasma-level-dependent manner (Martinet et al 1996). Unlike 
melatonin, however, agomelatine has anxiolytic properties in 
animal models of anxiety including the elevated plus maze, 
vogel conﬂ  ict (Millan et al 2005; den Boer et al 2006) and 
social defeat (Tuma et al 2005) models. It has been postulated 
that these effects are related to the receptor proﬁ  le (Millan 
et al 2005; Papp et al 2006).
Agomelatine has also demonstrated strong antidepressant-
like properties in several animal models of depression, including 
chronic mild stress (Papp et al 2003), learned helplessness (Ber-
taina-Anglade et al 2002), forced swimming (Bourin et al 2004), 
and a psychosocial stress model in tree shrews (Fuchs et al 2006). 
These preclinical ﬁ  ndings suggest that agomelatine, besides its 
antidepressant efﬁ  cacy, may be helpful in sleep promotion and 
in resetting the biological clock in humans.
Two additional candidate mechanisms underlying 
depression involve abnormalities of glucocorticoid receptor 
function (van Rossum et al 2006) and hippocampal 
neurogenesis (Duman and Monteggia 2006). Using 
transgenic mice with impaired glucocorticoid receptor 
function, Barden et al (2005) concluded that the behavioral 
effects of agomelatine are not associated with changes in 
hypothalamic-pituitary-adrenal axis activity. However, in 
another animal model of depression (the tree-shrew), Simon 
and colleagues (2004) showed that agomelatine reversed 
the increases in cortisol, but this may be as an indirect 
consequence of its antidepressant activity.
In keeping with recent evidence that depression is 
associated with a reduction in granule cell neurogenesis in the 
hippocampus and that antidepressants from disparate classes 
promote neurogenesis (Malberg and Schechter 2005), Banasr 
and colleagues (2006) found that agomelatine increased both 
cell proliferation and survival of newly formed cells.
Clinical studies
Available data from published agomelatine trials address ef-
ﬁ  cacy, dosing range, and tolerability with speciﬁ  c attention 
to sleep, sexual function, and abrupt discontinuation.
In an 8-week dose-finding study in over 700 patients, 
3 doses of agomelatine (1 mg, 5 mg, and 25 mg/day) 
were compared with placebo, using paroxetine 20 mg as 
an active comparator. The analyses supported agomela-
tine 25 mg as the most effective dose, based on a sig-
nificant difference from placebo on efficacy (p < 0.05) 
and rates of responders (p < 0.05) (Loo et al 2002). The Neuropsychiatric Disease and Treatment 2007:3(4) 425
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mean Hamilton Rating Scale for Depression (HAM-D; 
Hamilton 1960) score for the paroxetine group was also 
significantly lower than placebo (p < 0.05); however the 
rate of responders to paroxetine was not significantly 
different from placebo.
In a second study, Kennedy and Emsley (2006) evaluated 
agomelatine under placebo-controlled conditions for 6 weeks 
in 212 patients, with dose increase in a double blind fashion 
from 25 mg to 50 mg/day in patients who were considered 
to have not improved sufﬁ  ciently after 2 weeks. Patients 
treated with agomelatine had a signiﬁ  cantly lower mean 
HAM-D score at endpoint compared to placebo (14.1 ± 7.7 
vs 16.5 ± 7.4, p = 0.026). A drug-placebo difference of 2–3   
points is well within the range reported for currently available 
antidepressants. Using a response criterion of 50% reduction 
or more from baseline on HAM-D, there was a signiﬁ  cantly 
higher rate of response with agomelatine compared with 
placebo (49.1% vs 34.3%, p = 0.03).
In a sub-analysis involving the “severe subpopulation” 
(deﬁ  ned as those with a baseline HAM-D of 25 or higher), 
treatment with agomelatine resulted in a significantly 
lower mean HAM-D total score at endpoint compared with 
placebo (14.4 ± 7.9 vs 17.3 ± 7.2, p = 0.024) and a signiﬁ  cant 
difference in the percentage of responders compared with 
placebo (48.7% vs 30.7%, p = 0.024). This study also 
evaluated the effect of a dose increase from 25 mg to 50 mg in 
approximately one third of agomelatine- and placebo-treated 
patients, demonstrating a signiﬁ  cant advantage of the 50 mg 
dose over placebo (p = 0.045).
Agomelatine has also been compared with venlafaxine 
in two separate randomized double-blind trials (Kennedy 
and Guilleminault 2006). In a 12 week trial, 277 subjects 
were randomized to receive agomelatine at a fixed dose 
of 50 mg or venlafaxine XR 75 mg, increased to 150 mg 
after 2 weeks. Although the primary outcome measure 
was change in sexual function among sexually active 
remitted subjects, a secondary analysis showed that 
remission (defined as a final score of 12 or less on the 
Montgomery Asberg Depression Rating Scale [MADRS; 
Montgomery and Asberg 1979]) was achieved by a 
comparable percentage of agomelatine- and venlafaxine 
XR-treatment patients. A second study was primarily 
designed to compare subjective reports of sleep patterns. 
In a flexible dosing, 6 week design, 165 patients were 
randomized to receive agomelatine (25–50 mg) and 167 
were randomized to venlafaxine in the immediate release 
form (75–150 mg). Both groups experienced similar 
reductions in HAM-D scores and comparable percentage 
of responders (based on the usual 50% reduction from 
baseline) (Kennedy and Guilleminault 2006).
Preclinical evidence that agomelatine has anxiolytic 
effects is enhanced by ﬁ  ndings that anxiety symptoms 
in depressed patients are also responsive to agomelatine. 
In the original dose-finding study, anxiety symptoms 
were assessed using the Hamilton Anxiety Rating Scale 
(HAM-A; Hamilton 1959). In this study, agomelatine 25 
mg daily, but not agomelatine 1 mg or 5 mg, signiﬁ  cantly 
decreased anxiety symptoms compared with placebo 
(p < 0.05) (Loo et al 2002): further investigation is 
warranted in patients with anxiety disorders.
There is also preliminary evidence from an open-trial that 
agomelatine added to lithium or valproate rapidly reversed 
bipolar depression, supporting further investigation of 
agomelatine in bipolar disorder (Guelﬁ   and Calabrese 2005). 
Results from a relapse prevention study are required to con-
ﬁ  rm the beneﬁ  ts of agomelatine as a maintenance treatment 
in depression.
Special issues with agomelatine
Restoration of the sleep-wake cycle
Sleep disturbance is an omnipresent depressive symptom, 
which is helped by most currently available antidepressants. 
Unfortunately, effective hypnotic doses may also be 
accompanied by daytime drowsiness (eg, mirtazapine; 
Radhakishun et al 2000) or by disrupted sleep architecture 
(eg, ﬂ  uoxetine; Wilson and Argyropoulos 2005). Preclinical 
findings that agomelatine restores circadian rhythms 
(Armstrong et al 1993; Redman et al 1995) are further endorsed 
by evidence that agomelatine can phase shift temperature and 
hormonal release in healthy older men (Leproult et al 2005). 
With evidence to suggest that disruptions of the internal 
circadian rhythm system and the sleep-wake cycle may be 
relevant in the pathoetiology of depression (Boivin 2000), 
agomelatine should be particularly beneﬁ  cial in restoring a 
healthy sleep-wake cycle.
In a polysomnographic study in 15 depressed patients, 
agomelatine over 6 weeks produced clinically signiﬁ  cant 
improvements in reducing wake time after sleep onset, 
increasing total slow-wave sleep, and was also associated 
with favorable self reports of better quality of sleep and lack 
of daytime sleepiness (Quera-Salva et al 2005). The Cyclic 
Alternating Pattern (CAP) in non-rapid-eye-movement sleep 
was also signiﬁ  cantly improved after 7 days treatment with 
agomelatine compared with placebo (Lopes et al 2005). There 
were also signiﬁ  cant subjective advantages reported on the 
Leeds Sleep Evaluation Questionnaire (LSEQ; Parrott and Neuropsychiatric Disease and Treatment 2007:3(4) 426
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Hindmarsh 1978) on subjective sleep perceptions of “getting 
to sleep” and “quality of sleep” with agomelatine compared 
with venlafaxine after 1 week that remained signiﬁ  cant for 
the remainder of the 6 week trial (Guilleminault 2005). 
Together, these preliminary reports on sleep emphasize the 
early and sustained restorative effects of agomelatine in the 
absence of other adverse effects on sleep.
Sexual function
Sexual function (particularly drive and desire) is frequently 
impaired in untreated depression (Kennedy et al 1999) 
and treatment-emergent sexual dysfunction (more often in 
arousal, orgasm, or ejaculation difﬁ  culties) occurs with most 
currently prescribed antidepressants (Kennedy et al 2000; 
Clayton et al 2002) Mirtazapine represents an exception to 
this pattern of antidepressant-induced sexual dysfunction, 
a result that is thought to be related to its 5HT2C antagonist 
properties (Montgomery et al 2002). Since agomelatine 
also blocks the 5HT2C receptor, it has been of considerable 
interest throughout the drug development program to 
systematically evaluate sexual function before and during 
agomelatine treatment in depressed patients. The sexual 
proﬁ  le of agomelatine has consistently emerged as favorable, 
whether in studies using speciﬁ  c rating scales (Sex Effects 
Scale [SexFX; Kennedy et al 2006] or Arizona Sexual 
Experience Scale [ASEX; McGahuey et al 2000]) or based 
on spontaneously reported adverse events (Kennedy 2006). In 
one of these reports, sexual side-effects were compared in a 
depressed population during treatment with agomelatine and 
venlafaxine over 12 weeks. A signiﬁ  cantly greater percentage 
of sexually active remitted patients in the agomelatine 
group reported no sexual dysfunction (80%) compared with 
just over 50% in the venlafaxine group (Kennedy 2005). 
Spontaneously reported sexual side-effects with agomelatine 
were also not different from placebo (Kennedy 2006).
General aspects of safety 
and tolerability
Agomelatine has a favorable side-effect proﬁ  le that has been 
indistinguishable from placebo in several clinical trials (Loo 
et al 2002; Kennedy and Emsley 2006) and superior to parox-
etine – paroxetine showed signiﬁ  cantly more gastrointestinal 
side-effects than placebo (Loo et al 2002). There have been 
no more reports of adverse effects on cardiovascular, hepatic, 
or renal function and no other laboratory abnormalities with 
agomelatine than with placebo.
The effect of abruptly discontinuing agomelatine has 
been evaluated in a double-blind, placebo-controlled 
comparison with paroxetine (Montgomery et al 2004). After 
12 weeks of double-blind treatment with agomelatine 25 
mg or paroxetine 20 mg daily, sustained remitted depressed 
patients were randomized for 2 weeks to remain on their 
index antidepressant or switch to placebo. Discontinua-
tion emergent signs and symptoms were evaluated using a 
validated scale (Rosenbaum et al 1998). In contrast to the 
paroxetine discontinuation group, there was no increase in 
discontinuation emergent signs and symptoms in the group 
who abruptly discontinued agomelatine.
Conclusion
As an antidepressant with unique effects on melatonergic and 
5HT2C receptors, agomelatine represents a promising advance 
in the treatment of major depressive disorder. Beyond a role 
in treating major depressive disorder, agomelatine may also 
represent a treatment option for other disorders including 
bipolar disorder, and generalized anxiety disorder.
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